Axsome Therapeutics

Yahoo Finance • yesterday

Axsome Faces Key Auvelity FDA Call And Insider Sentiment Test

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Axsome Therapeutics (NasdaqGM:AXSM) is awaiting an FDA decision this month on Auvelity for agitation associated with Alzhei... Full story

Yahoo Finance • 3 days ago

Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says

Axsome Therapeutics (AXSM) could see meaningful upside ahead of a US Food and Drug Administration de PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 days ago

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial... Full story

Yahoo Finance • 12 days ago

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

Axsome Therapeutics, Inc. Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS portfolio with a novel mecha... Full story

Yahoo Finance • 26 days ago

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics(NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter. What happened According to a Securities and Exchange Co... Full story

Yahoo Finance • last month

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether certain officers and directors of Atkore Inc. (NYSE: ATKR), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Capricor Therapeutics, Inc. (NASDAQ: CAPR),... Full story

Yahoo Finance • last month

Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory

We came across a bullish thesis on Axsome Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on AXSM. Axsome Therapeutics, Inc.'s share was trading at $163.19 as of February 26th. AXSM’s forward... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary

Axsome Therapeutics, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Drivers Achieved 66% annual revenue growth driven by Auvelity's rapid uptake, which surpassed $500,000,000 in net sales in its third ful... Full story

Yahoo Finance • 2 months ago

Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036

Key Points Axsome Therapeutics' lineup and late-stage pipeline could help drive strong sales growth for a while. The biotech won't run into patent cliffs in the near future, either. 10 stocks we like better than Axsome Therapeutics › Axs... Full story

Yahoo Finance • 2 months ago

Boeing Holds In Buy Zone, Leads 5 Stocks To Watch In Short Trading Week

Five stocks with strong technical action from a variety of groups, include Boeing, Viking Holdings, TJX and an AI construction play. Continue Reading... Full story

Yahoo Finance • 2 months ago

Should You Buy Axsome Therapeutics Stock Before Feb. 23?

Axsome Therapeutics(NASDAQ: AXSM) has been a red-hot stock to own over the past 12 months. During that stretch, it has soared by around 75%, dwarfing the performance of the S&P 500, which is up by 15% over that same time frame. The healthc... Full story

Yahoo Finance • 2 months ago

1 High-Flying Stock With More Upside Ahead

Over the past five years, Axsome Therapeutics(NASDAQ: AXSM) has been on fire. The company has crushed the market in this period on the back of solid clinical and regulatory progress. At this point, it's fair to ask whether there is any ups... Full story

Yahoo Finance • 2 months ago

Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates

Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the mid-cap stocks to buy according to top investors. On January 20, H.C. Wainwright boosted its price target for Axsome Therapeutics Inc. (NASDAQ:AXSM) to $260 from $200 and kept a Buy ra... Full story

Yahoo Finance • 3 months ago

US Equities Fall in Final 2025 Session; Indexes Still Post Solid Annual Gains

US equity benchmarks fell Wednesday in the final session of 2025 as stock gauges still logged solid PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Wednesday afternoon with the NYSE Health Care Index dropping 0.5% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Why Axsome Therapeutics Stock Rocketed Higher to End 2025

Key Points Axsome just received priority review designation for its most important drug. Auvelity is an oral medication already approved for adults with major depressive disorder (MDD). Auvelity sales soared 69% in Q3. 10 stocks we like b... Full story

Yahoo Finance • 3 months ago

Top Midday Stories: Nvidia Approaches TSMC in Quest to Boost H200 Chip Production; Corcept Faces Setback From FDA on Hypertension Drug

All three major US stock indexes were down in late-morning trading Wednesday as the year winds to a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the t... Full story

Yahoo Finance • 3 months ago

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous syst... Full story

Yahoo Finance • 4 months ago

Dow Jones Futures Due After Two Bullish Days; Palantir, GE Lead 12 Stocks In Buy Zones

Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys. Continue Reading... Full story